SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Clement Yves)
 

Sökning: WFRF:(Clement Yves) > Disseminated tumour...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006475naa a2200793 4500
001oai:lup.lub.lu.se:62cfd7fb-e0b6-4b26-bfa8-eb45bf747e9b
003SwePub
008210816s2021 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/62cfd7fb-e0b6-4b26-bfa8-eb45bf747e9b2 URI
0247 a https://doi.org/10.1016/j.ejca.2021.06.0282 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Hartkopf, Andreas D.u University of Tübingen4 aut
2451 0a Disseminated tumour cells from the bone marrow of early breast cancer patients : Results from an international pooled analysis
264 1b Elsevier BV,c 2021
300 a 10 s.
520 a Purpose: Presence of disseminated tumour cells (DTCs) in the bone marrow (BM) has been described as a surrogate of residual disease in patients with early breast cancer (EBC). PADDY (Pooled Analysis of DTC Detection in Early Breast Cancer) is a large international analysis of pooled data that aimed to assess the prognostic impact of DTCs in patients with EBC. Experimental design: Individual patient data were collected from 11 centres. Patients with EBC and available follow-up data in whom BM sampling was performed at the time of primary diagnosis before receiving any anticancer treatment were eligible. DTCs were identified by antibody staining against epithelial cytokeratins. Multivariate Cox regression was used to compare the survival of DTC-positive versus DTC-negative patients. Results: In total, 10,307 patients were included. Of these, 2814 (27.3%) were DTC-positive. DTC detection was associated with higher tumour grade, larger tumour size, nodal positivity, oestrogen receptor and progesterone receptor negativity, and HER2 positivity (all p < 0.001). Multivariate analyses showed that DTC detection was an independent prognostic marker for overall survival, disease-free survival and distant disease-free survival with hazard ratios (HR) and 95% confidence intervals (CI) of 1.23 (95% CI: 1.06–1.43, p = 0.006), 1.30 (95% CI: 1.12–1.52, p < 0.001) and 1.30 (95% CI: 1.08–1.56, p = 0.006), respectively. There was no association between locoregional relapse-free survival and DTC detection (HR 1.21; 95% CI 0.68–2.16; p = 0.512). Conclusions: DTCs in the BM represent an independent prognostic marker in patients with EBC. The heterogeneous metastasis-initiating potential of DTCs is consistent with the concept of cancer dormancy.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Bone marrow
653 a Disseminated tumour cells
653 a Early breast cancer
653 a Micrometastases
653 a Prognosis
653 a Tumour staging
7001 a Brucker, Sara Y.u University of Tübingen4 aut
7001 a Taran, Florin Andreiu University of Tübingen,University Medical Center Freiburg4 aut
7001 a Harbeck, Nadiau Ludwig-Maximilian University of Munich4 aut
7001 a von Au, Alexandrau University Hospital Heidelberg4 aut
7001 a Naume, Bjørnu Oslo university hospital4 aut
7001 a Pierga, Jean Yvesu Curie Institute, Paris4 aut
7001 a Hoffmann, Oliveru University Hospital Essen4 aut
7001 a Beckmann, Matthias W.u University Hospital Erlangen4 aut
7001 a Rydén, Lisau Lund University,Lunds universitet,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Breast Cancer Surgery,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)pat-lry
7001 a Fehm, Tanjau Heinrich Heine University Düsseldorf4 aut
7001 a Aft, Rebeccau Washington University in St. Louis4 aut
7001 a Solà, Montserratu Hospital Universitari Germans Trias i Pujol4 aut
7001 a Walter, Vincentu University of Tübingen4 aut
7001 a Rack, Brigitteu University Hospital of Ulm4 aut
7001 a Schuetz, Florianu University Hospital Heidelberg4 aut
7001 a Borgen, Elinu Oslo university hospital4 aut
7001 a Ta, Minh Hanhu Curie Institute, Paris4 aut
7001 a Bittner, Ann Kathrinu University Hospital Essen4 aut
7001 a Fasching, Peter A.u University Hospital Erlangen4 aut
7001 a Fernö, Mårtenu Lund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Personalized Breast Cancer Treatment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)onk-mfe
7001 a Krawczyk, Nataliau Heinrich Heine University Düsseldorf4 aut
7001 a Weilbaecher, Katherineu Washington University in St. Louis4 aut
7001 a Margelí, Mireiau Institute for Health Science Research Germans Trias i Pujol (IGTP)4 aut
7001 a Hahn, Markusu University of Tübingen4 aut
7001 a Jueckstock, Juliau Ludwig-Maximilian University of Munich4 aut
7001 a Domschke, Christophu University Hospital Heidelberg4 aut
7001 a Bidard, Francois Clementu Curie Institute, Paris4 aut
7001 a Kasimir-Bauer, Sabineu University Hospital Essen4 aut
7001 a Schoenfisch, Birgittu University of Tübingen4 aut
7001 a Kurt, Ayse G.u Ludwig-Maximilian University of Munich4 aut
7001 a Wallwiener, Markusu University Hospital Heidelberg4 aut
7001 a Gebauer, Gerhardu Asklepios Kliniken Hamburg GmbH4 aut
7001 a Klein, Christoph A.u University of Regensburg4 aut
7001 a Wallwiener, Diethelmu University of Tübingen4 aut
7001 a Janni, Wolfgangu University Hospital of Ulm4 aut
7001 a Pantel, Klausu University Medical Center Hamburg-Eppendorf4 aut
7102 a University of Tübingenb University Medical Center Freiburg4 org
7730 t European Journal of Cancerd : Elsevier BVg 154, s. 128-137q 154<128-137x 0959-8049
8564 u http://dx.doi.org/10.1016/j.ejca.2021.06.028y FULLTEXT
8564 8u https://lup.lub.lu.se/record/62cfd7fb-e0b6-4b26-bfa8-eb45bf747e9b
8564 8u https://doi.org/10.1016/j.ejca.2021.06.028

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy